Inhibition of CRTh2 activation has been proposed as a treatment strategy for asthma inflammation by inhibiting the release of critical cytokines, including IL-5, IL-4, IL-13, IL-33, and IL-25, and blocking eosinophil and basophil degranulation. Here, PTGDR2 is linked to asthma.